As such, lifestyle intervention is the recommended first-line treatment, even in the presence of medications for obesity, T2D, and the first liver-targeted drug for MASH, Rezdiffra (resmetirom
D.IngenitoE
Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ, Hovingh GK, Kitzman DW, Mller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
In vitro studies showed exacerbation in areas that are thinner and experience higher UV-A penetration